JP2011508875A5 - - Google Patents

Download PDF

Info

Publication number
JP2011508875A5
JP2011508875A5 JP2010538902A JP2010538902A JP2011508875A5 JP 2011508875 A5 JP2011508875 A5 JP 2011508875A5 JP 2010538902 A JP2010538902 A JP 2010538902A JP 2010538902 A JP2010538902 A JP 2010538902A JP 2011508875 A5 JP2011508875 A5 JP 2011508875A5
Authority
JP
Japan
Prior art keywords
gpcr
variant
parent
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011508875A (ja
JP5763343B2 (ja
Filing date
Publication date
Priority claimed from GBGB0724860.2A external-priority patent/GB0724860D0/en
Application filed filed Critical
Publication of JP2011508875A publication Critical patent/JP2011508875A/ja
Publication of JP2011508875A5 publication Critical patent/JP2011508875A5/ja
Application granted granted Critical
Publication of JP5763343B2 publication Critical patent/JP5763343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538902A 2007-12-20 2008-12-19 スクリーニング Active JP5763343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0724860.2 2007-12-20
GBGB0724860.2A GB0724860D0 (en) 2007-12-20 2007-12-20 Screening
PCT/GB2008/004223 WO2009081136A2 (en) 2007-12-20 2008-12-19 Screening

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015117562A Division JP6425620B2 (ja) 2007-12-20 2015-06-10 スクリーニング

Publications (3)

Publication Number Publication Date
JP2011508875A JP2011508875A (ja) 2011-03-17
JP2011508875A5 true JP2011508875A5 (cg-RX-API-DMAC7.html) 2012-09-13
JP5763343B2 JP5763343B2 (ja) 2015-08-12

Family

ID=39048448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010538902A Active JP5763343B2 (ja) 2007-12-20 2008-12-19 スクリーニング
JP2015117562A Active JP6425620B2 (ja) 2007-12-20 2015-06-10 スクリーニング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015117562A Active JP6425620B2 (ja) 2007-12-20 2015-06-10 スクリーニング

Country Status (8)

Country Link
US (5) US8790933B2 (cg-RX-API-DMAC7.html)
EP (2) EP2573563B1 (cg-RX-API-DMAC7.html)
JP (2) JP5763343B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008339595C1 (cg-RX-API-DMAC7.html)
CA (1) CA2710145C (cg-RX-API-DMAC7.html)
ES (1) ES3006458T3 (cg-RX-API-DMAC7.html)
GB (2) GB0724860D0 (cg-RX-API-DMAC7.html)
WO (1) WO2009081136A2 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2456236B8 (en) * 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2483661B1 (en) 2009-09-28 2020-02-05 Koninklijke Philips N.V. Substance determining apparatus and method
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP3333185A1 (en) 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs
WO2011033322A2 (en) * 2011-01-07 2011-03-24 Heptares Therapeutics Ltd Crystal structure
KR101963914B1 (ko) 2011-02-23 2019-03-29 매사추세츠 인스티튜트 오브 테크놀로지 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법
WO2012120315A2 (en) * 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
EP2578695A1 (en) * 2011-10-05 2013-04-10 Albert-Ludwigs-Universität Freiburg Assay for Clostridium botulinum Neurotoxin
ES2676827T3 (es) 2012-06-01 2018-07-25 Heptares Therapeutics Limited Ensayos
US20150216977A1 (en) 2012-09-18 2015-08-06 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
WO2014045081A1 (en) * 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
DK2951201T3 (en) * 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
WO2014124020A1 (en) * 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
CN105593240B (zh) * 2013-06-11 2024-05-31 保罗·谢勒学院 用于以单氨基酸分辨率确定可突变配体-gpcr结合的方法以及突变配体和gpcr对
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
GB201415094D0 (en) 2014-08-26 2014-10-08 Heptares Therapeutics Ltd GPCR receptor binding domain and uses thereof
EP3839061B1 (en) 2014-10-27 2022-12-07 King Abdullah University Of Science And Technology Methods and systems for identifying ligand-protein binding sites
EP3212784B1 (en) 2014-10-31 2019-05-29 Abilita Bio, Inc. Modified membrane spanning proteins and methods for the preparation and use thereof
US20180224438A1 (en) * 2015-08-10 2018-08-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Stabilized vesicle-functionalized microparticles for chemical separations and rapid formation of polymer frits in silica capillaries using spatially-defined thermal polymerization
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
EP3452516A4 (en) 2016-05-04 2019-11-27 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US10320280B2 (en) * 2016-11-08 2019-06-11 Analog Devices Global Unlimited Company LC filter including coupled inductors for reducing ripple in switching power supplies
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
FR3069644B1 (fr) * 2017-07-28 2024-07-12 Cisbio Bioassays Methode pour mesurer la modulation de l'activation d'un recepteur couple a une proteine g
AU2018358804A1 (en) * 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US11262309B2 (en) * 2018-07-11 2022-03-01 Advanced Cytometry Instrumentation Systems, Llc Methods for lipid measurement in cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CA3108892A1 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
EP3914916A1 (en) * 2019-01-22 2021-12-01 InterAx Biotech AG Beta-arrestin mutants
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020243601A1 (en) 2019-05-31 2020-12-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Synthesis of nanoscint particles
EP3953477A4 (en) 2019-06-06 2022-06-22 Inscripta, Inc. HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
WO2021064610A1 (en) * 2019-10-01 2021-04-08 Ac Immune Sa Micro-radiobinding assays for ligand screening
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
AU2020402526B2 (en) 2019-12-10 2025-01-23 Inscripta, Inc. Novel MAD nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
WO2021126886A1 (en) 2019-12-18 2021-06-24 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
CN115135370A (zh) 2020-01-27 2022-09-30 因思科瑞普特公司 电穿孔模块和仪器
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
CA3204158A1 (en) 2021-01-04 2022-07-07 Juhan Kim Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
CN114836517B (zh) * 2022-04-20 2026-03-17 合肥中科普瑞昇生物医药科技有限公司 一种A2aR拮抗剂的高通量筛选体系及其应用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
EP4689151A2 (en) * 2023-03-28 2026-02-11 Ibrahim, Yasir, H. Methods of enzyme purification using g-proteins as controllable affinity probes
EP4621788A1 (en) * 2024-03-22 2025-09-24 Genome Research Limited Gpcr
WO2026018204A1 (en) * 2024-07-18 2026-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for the quantification of plasma amyloid-beta biomarkers in alzheimer's disease
WO2026025080A1 (en) * 2024-07-26 2026-01-29 Bioventures, Llc Enable discovery of bcl-2 family inhibitors targeting mode ii complexes

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
JP3147916B2 (ja) * 1991-03-08 2001-03-19 森永製菓株式会社 体外免疫方法
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US20030036092A1 (en) * 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5585277A (en) * 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
WO1995032425A1 (en) 1994-05-23 1995-11-30 Smithkline Beecham Corporation Encoded combinatorial libraries
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
EP0906339A2 (en) 1996-03-27 1999-04-07 NG, Gordon, Y., K. Receptor and transporter antagonists
EP0910648A1 (en) * 1996-04-15 1999-04-28 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
EP1068356B8 (en) * 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
US6475733B1 (en) * 1998-04-06 2002-11-05 Lerner Pharmaceuticals, Inc. Cell surface receptors for the detection and identification of compounds
US6692696B1 (en) * 1998-06-18 2004-02-17 ARETé ASSOCIATES Biosensor
US7094593B1 (en) * 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
WO2000070343A2 (en) * 1999-05-14 2000-11-23 Repliscent, Inc. G-protein coupled receptor based biosensors and sense replication systems
IL149569A0 (en) 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
JP2003523744A (ja) * 2000-02-09 2003-08-12 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Ccr5に対する抗体
CA2403784A1 (en) * 2000-03-21 2001-09-27 Consensus Pharmaceuticals, Inc. Binding compounds and methods for identifying binding compounds
CA2402392A1 (en) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
US7678539B2 (en) * 2000-08-10 2010-03-16 Corning Incorporated Arrays of biological membranes and methods and use thereof
AU2001286945A1 (en) * 2000-08-30 2002-03-13 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6448377B1 (en) * 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
WO2002059346A2 (en) 2000-10-26 2002-08-01 New England Medical Center Hospitals, Inc. Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
US20030232331A1 (en) 2000-12-05 2003-12-18 Casman Stacie J. Novel proteins and nucleic acids encoding same
EP1379656A2 (en) 2001-02-14 2004-01-14 Amgen Inc. G-protein coupled receptor molecules and uses thereof
CN1516706A (zh) 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
JPWO2002079784A1 (ja) 2001-03-30 2004-07-22 サントリー株式会社 G蛋白質結合型レセプターの構造モデルおよび当該構造モデルを用いたg蛋白質結合型レセプターに結合するリガンドの設計方法
US20030129649A1 (en) * 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US20050009204A1 (en) * 2003-07-11 2005-01-13 Ye Fang Multiplexed binding assays for receptor arrays
DE60214869T2 (de) 2001-10-25 2007-04-12 Astex Technology Ltd., Cambridge Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung
US7115377B2 (en) * 2001-10-26 2006-10-03 Atto Bioscience, Inc. Cell-based assays for G-protein-coupled receptor-mediated activities
AU2003227268A1 (en) 2002-03-28 2003-10-13 Takeda Chemical Industries, Ltd. Novel screening method
JP2004238384A (ja) 2002-03-28 2004-08-26 Takeda Chem Ind Ltd 新規スクリーニング方法
CA2483701A1 (en) 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Constitutively active histamine h3 receptor mutants and uses thereof
EP1549318B1 (en) * 2002-05-01 2010-02-17 Vertex Pharmaceuticals Incorporated Crystal structure of aurora-2 protein and binding pockets thereof
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
US20040096914A1 (en) * 2002-11-20 2004-05-20 Ye Fang Substrates with stable surface chemistry for biological membrane arrays and methods for fabricating thereof
US7745161B2 (en) * 2003-12-19 2010-06-29 Palo Alto Research Center Incorporated Amplification of enzymatic reactions for use with an enthalpy array
US20050287519A1 (en) * 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
KR100575682B1 (ko) * 2004-05-24 2006-05-03 엘지전자 주식회사 실외기간 균압관을 구비한 공기조화기
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
WO2006007857A1 (en) * 2004-07-23 2006-01-26 Hvidovre Hospital Bilf1, a constitutive active g-protein coupled receptor
US20060188964A1 (en) 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
JP2006340717A (ja) 2005-05-11 2006-12-21 Sekisui Chem Co Ltd Gタンパク質共役型受容体に対する結合性評価方法及び評価用組成物、融合タンパク質、並びに、遺伝子
FR2890174B1 (fr) 2005-08-30 2009-04-24 Cis Bio Internat Sa Procede pour la mise en evidence d'un processus biologique par mesure d'un fret
US20070154947A1 (en) * 2005-08-31 2007-07-05 The Trustees Of Princeton University Chemical biodiscriminator
US20070196389A1 (en) * 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
WO2009051769A1 (en) 2007-10-17 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for crystallizing g protein-coupled receptors
CA2701283C (en) * 2007-10-22 2014-07-15 The Scripps Research Institute Methods and compositions for obtaining high-resolution crystals of membrane proteins
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) * 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) * 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP3333185A1 (en) * 2010-08-20 2018-06-13 Heptares Therapeutics Limited Mutant gpcrs
EP2611826B1 (en) 2010-08-30 2016-09-21 Confometrx, Inc. Method and composition for crystallizing a family c gpcr
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP2014516963A (ja) 2011-05-13 2014-07-17 レセプトス インコーポレイテッド Gタンパク質共役レセプターを結晶化するための新規融合パートナー
WO2013021206A2 (en) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Stable proteins
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
ES2676827T3 (es) 2012-06-01 2018-07-25 Heptares Therapeutics Limited Ensayos
US20150261911A1 (en) 2014-03-13 2015-09-17 Heptares Therapeutics Limited Crystal structure

Similar Documents

Publication Publication Date Title
US20210148939A1 (en) Methods for screening for binding partners of g-protein coupled receptors
CN102257390B (zh) 半乳凝素-3免疫测定法
Vidic et al. Quantitative assessment of olfactory receptors activity in immobilized nanosomes: a novel concept for bioelectronic nose
Wang et al. Microarray based screening of peptide nano probes for HER2 positive tumor
Locatelli-Hoops et al. Surface plasmon resonance applied to G protein-coupled receptors
Ranjbari et al. Surface plasmon resonance biosensors for early troponin detection
Alves et al. Plasmon resonance methods in GPCR signaling and other membrane events
CN104903727B (zh) 诊断、预后、治疗和筛选方案
US20200231949A1 (en) G proteins
WO2013035799A1 (ja) ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
TW201818958A (zh) 製造和使用可溶性主要組織相容性複合體(mhc)分子類之方法
Murray et al. Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2
CN110456042A (zh) 血清学生物标志物在制备试剂盒和/或芯片中的应用、试剂盒或芯片及其制备方法
CN104126122B (zh) 与胰岛素受体族反应抗体结合性能调节剂之识别
US20030059827A1 (en) Engineered protein binding domains and methods and systems for their design and use
Haun et al. Using engineered single-chain antibodies to correlate molecular binding properties and nanoparticle adhesion dynamics
Ballard et al. Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling
US10429300B2 (en) Surface plasmon resonance approach to monitor protein-ligand interactions
Kriechbaumer et al. Quantification of ligand binding to G-protein coupled receptors on cell membranes by ellipsometry
CN114402201A (zh) 川崎病罹患判定试剂盒和川崎病罹患判定方法
Fang et al. with stage progression. Taken together, these data suggest that the level of EphA10 expression partly contributes to breast cancer progression. Next, we evaluated the relationship between EphA10 protein expression and clinicopathological characteristics.